首页> 外文期刊>World Journal of Gastroenterology >Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV
【24h】

Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV

机译:Legalon-SIL下调表达全长HCV的人肝细胞中的HCV核心和NS5A

获取原文
           

摘要

AIM: To determine the effect of Legalon-SIL (LS) on hepatitis C virus (HCV) core and NS5A expression and on heme oxygenase-1 (HMOX-1) and its transcriptional regulators in human hepatoma cells expressing full length HCV genotype 1b. METHODS: CON1 cells were treated with 50 μmol/L or 200 μmol/L LS. Cells were harvested after 2, 6 and 24 h. HCV RNA and protein levels were determined by quantitative real-time polymerase chain reaction and Western blotting, respectively. RESULTS: HCV RNA (core and NS5A regions) was decreased after 6 h with LS 200 μmol/L (P P P P P P CONCLUSION: Our results demonstrate that treatment with LS downregulates HCV core and NS5A expression in CON1 cells which express full length HCV genotype 1b, and suggests that LS may prove to be a valuable alternative or adjunctive therapy for the treatment of HCV infection.
机译:目的:确定Legalon-SIL(LS)对表达全长HCV基因型1b的人肝癌细胞中丙型肝炎病毒(HCV)核心和NS5A表达以及对血红素加氧酶-1(HMOX-1)及其转录调节剂的影响。方法:CON1细胞用50μmol/ L或200μmol/ L LS处理。在2、6和24小时后收获细胞。 HCV RNA和蛋白质水平分别通过实时定量聚合酶链反应和蛋白质印迹法确定。结果:LS 200μmol/ L 6 h后,HCV RNA(核心和NS5A区域)降低(PPPPPP结论):我们的结果表明,LS处理下调了表达全长HCV基因型1b的CON1细胞中的HCV核心和NS5A表达,并且提示LS可能被证明是治疗HCV感染的有价值的替代或辅助疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号